Group 1: Banking Sector Insights - The report anticipates a continued decline in credit activity due to insufficient demand and seasonal factors, with November loan growth expected to show a year-on-year decrease [1] - Government bonds remain the primary contributor to social financing, with the month-end growth rate projected to drop to approximately 8.4% [1] - M2 growth is expected to remain stable, while M1 growth is forecasted to decline, leading to a slight widening of the M2-M1 growth differential compared to the previous month [1] Group 2: Company Research on Andisu - Andisu is set to launch a new generation of sodium butyrate products, Sanion Tetra, and has released the latest version of the "Mackev Nutrition Guide" to assist global feed manufacturers [2] - The company's projected net profit attributable to shareholders for 2025, 2026, and 2027 is estimated at 1.318 billion, 1.535 billion, and 1.784 billion respectively, maintaining a "buy" rating [2]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is implementing a "dual pillar" strategy to enhance its global business development, focusing on solidifying its leadership in the methionine market while expanding its high-value specialty products [7] - The Quanzhou solid methionine project is progressing well, expected to be operational by 2027, which will support the company's global capacity optimization [7] - Revenue for the first three quarters of 2025 increased by 13.67% year-on-year, while net profit slightly decreased by 1.29% due to rising raw material costs and product price declines [7] Financial Projections - Total revenue is projected to reach 15,534 million yuan in 2024, with a year-on-year growth of 17.83%, and is expected to grow to 21,718 million yuan by 2027 [1][8] - The net profit attributable to the parent company is forecasted to be 1,204 million yuan in 2024, with a significant increase to 1,701 million yuan by 2027, reflecting a growth rate of 20.84% [1][8] - The earnings per share (EPS) is expected to rise from 0.45 yuan in 2024 to 0.63 yuan in 2027 [1][8] Market Position and Competitive Advantage - The company is positioned as a global leader in the methionine industry, with a strong focus on research and development to drive future growth [7] - The integration of resources from Sinochem in the Quanzhou project enhances cost competitiveness, leveraging location advantages [7]

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Insights - The company is set to launch a new generation of sodium butyrate products, Sanion Tetra, to strengthen its leadership in animal health management. Additionally, the updated McCaw® Nutrition Guide will provide global feed manufacturers with systematic vitamin nutrition references [1][2]. - The company is expanding its product and service matrix, focusing on high-concentration sodium butyrate solutions, which align with the global trend of reducing antibiotic use in livestock and promoting sustainable nutrition [2][3]. - The company is accelerating the development of specialty products and deepening its layout in the animal nutrition and health sector, supported by a "dual pillar" strategy that aims to balance its business structure while maintaining its global leadership in methionine [3]. Summary by Sections Product Development - The launch of Sanion Tetra aims to enhance the company's product matrix in animal health resilience management and respond to industry trends [2]. - The updated McCaw® Nutrition Guide expands the classification of animal species and production stages, providing comprehensive updates on recommended values based on current feed efficiency levels and new formulation technologies [2]. Financial Forecast and Valuation - The company is expected to benefit from its dual pillar strategy while maintaining its leadership in the methionine industry. The profit forecast for 2025-2027 is as follows: net profit of 1.318 billion, 1.535 billion, and 1.784 billion yuan, with corresponding EPS of 0.49, 0.57, and 0.67 yuan per share [4][10]. - Revenue projections for 2025-2027 are 17.866 billion, 20.545 billion, and 23.627 billion yuan, with growth rates of 15.01%, 15.00%, and 15.00% respectively [10]. Profitability and Efficiency - The company is expected to maintain a gross margin of 28.8% in 2025, with a projected return on equity (ROE) of 7.97% [12][13]. - The operating profit margin is forecasted to be 11.1% in 2025, indicating a strong operational efficiency [12].

蓝星安迪苏股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司(以下简称"公司")于 2025 年 9 月 25 日召开 2025 年 年第三次临时股东大会，审议通过了《关于取消监事会及监事暨修订<公司章程> 的议案》，依据修订后的《公司章程》，公司董事会由 11 董事组成，其中包括 1 名 职工代表董事。根据《公司法》的相关规定，董事会中的职工代表由公司职工通 过职工代表大会、职工大会或者其他形式民主选举产生。 证券代码：600299 证券简称：安迪苏 公告编号：2025-052 蓝星安迪苏股份有限公司董事会 2025 年 12 月 1 日 附：职工代表董事简历 姓名 主要工作经历 潘勇 生于 1978 年，汉族，中国籍，应用化学专业本科，学士。曾在 帝斯曼东方南京化工有限公司担任轮班班长，拜耳聚氨酯上海 有限公司担任运行主管，瓦克化学南京有限公司担任助理工厂 经理，2014 年 6 月加入蓝星安迪苏南京有限公司担任中游生产 经理，2018 年 7 月到 2020 ...

北京市金杜律师事务所上海分所 关于蓝星安迪苏股份有限公司 2025 年第四次临时股东会 北京市金杜律师事务所上海分所（以下简称金杜）接受蓝星安迪苏股份有限公司 （以下简称安迪苏或公司）的委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会（以下简称中国证监会）《上市公司股东会规则》（以下简称《股东会规则》） 等中华人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香 港特别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规及规 范性文件和现行有效的公司章程有关规定，指派律师出席了公司于 2025 年 12 月 1 日召 开的 2025 年第四次临时股东会（以下简称本次股东会），并就本次股东会相关事项出 具本法律意见书。 为出具本法律意见书，金杜律师审查了安迪苏提供的以下文件，包括但不限于： 1. 经安迪苏 2025 年第三次临时股东大会审议通过的《蓝星安迪苏股份有限公司 章程》（以下简称《公司章程》）； 2. 安迪苏 2025 年 10 月 31 日刊登于巨潮资讯网及上海证券交易所网站的《蓝星 安迪苏 ...

本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 12 月 1 日 证券代码：600299 证券简称：安迪苏 公告编号：2025-051 蓝星安迪苏股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (二)股东会召开的地点：北京市朝阳区北土城西路 9 号蓝星大厦会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 147 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 2,310,475,745 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 86.1506 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，公司董事长郝志刚先生主持会议，采取现场 投票和网络投票相结合的表决方式。会议召集、召开程序符合《中华人民共和国 ...

Summary of Earnings Estimates for China Commodities Industry Overview - The report focuses on the **China commodities** sector, specifically covering various sub-sectors including steel, coal, cement, aluminum, copper, gold, EV metals, paper, and agriculture. Key Points in Earnings Estimates Revisions - **General Update**: Earnings estimates for China commodities have been refreshed to reflect mark-to-market price changes for Q3 2025 and the current quarter. Target price changes range from -5% to +5%, with investment ratings remaining unchanged. The changes are not viewed as material, and the overall investment thesis remains intact [1][2]. Steel Sector - **Baosteel and Maanshan-H/A**: Earnings estimates cut by 3% to 5%. Loss estimates for Angang-H/A increased by 4% for 2025E [9]. Coal Sector - **Shenhua-H/A, Yankuang-H/A, Chinacoal-H/A**: Earnings estimates updated by -3% to +5% for 2025-27E based on recent coal price trends. Chinacoal-H/A target price adjusted to HK$6.5 from HK$6.4, maintaining a Sell rating [9]. Cement Sector - **CNBM, WCC, BBMG-H/A, Conch-H/A, CRBMT**: Earnings estimates updated by -5% to +3% for 2025-27E, reflecting recent unit gross profit trends [9]. Aluminum Sector - **Chalco-H/A and Hongqiao**: Earnings estimates adjusted by -5% to +5% for 2025-27E based on mark-to-market aluminum and alumina prices. Hongqiao target price fine-tuned to HK$20.0 from HK$19.6, maintaining a Neutral rating [9]. Base Metals (Copper and Gold) - **Zijin-H/A, JXC-H/A, CMOC-H/A, MMG, Zhaojin**: Earnings estimates updated by -5% to +5% for 2025-27E to reflect mark-to-market prices of copper and other metals [9]. EV Metals - **Huayou and GEM**: Earnings estimates adjusted by -3% to +5% for 2025-27E based on mark-to-market nickel/cobalt prices and cathode spreads. Huayou's target price fine-tuned to Rmb32.6 from Rmb32.4, maintaining a Sell rating [9]. Paper Sector - **ND Paper and Sun Paper**: Earnings estimates updated by 0% to 2% for 2025-27E to reflect mark-to-market paper prices [10]. Agriculture Sector - **Hog and Feed Coverage**: Earnings estimates revised by -5% to +3% for companies like Wens, New Hope, Haid, and Dabeinong, incorporating mark-to-market hog and feed prices. For animal health and conventional seeds, estimates revised by -5% to -2% [10][13]. Target Price Methodologies and Risks - **Cement Companies**: Target prices based on historical P/B vs. ROE correlations. Key risks include weaker-than-expected construction demand and slower unauthorized cement capacity exit [14]. - **Base Metals**: Target prices based on historical P/B vs. ROE correlations. Key risks include lower commodity prices and operational risks [14]. Additional Insights - The report emphasizes the importance of considering these estimates as part of a broader investment decision-making process, highlighting potential conflicts of interest due to Goldman Sachs' business relationships with covered companies [3]. This summary encapsulates the key updates and insights from the earnings estimates for the China commodities sector, providing a comprehensive overview of the changes and their implications for investors.

Core Points - Multiple listed companies received regulatory notices regarding suspected violations of information disclosure laws and regulations on November 28 [1][4][8][11][17] Group 1: Haide Co., Ltd. - Haide Co., Ltd. received a notice from the CSRC for suspected information disclosure violations, leading to an investigation of the company and its actual controller Wang Guangxi [1] - The company acknowledged historical non-operating fund occupation, which was fully returned by April 24, and has since implemented training and corrective measures to improve compliance and disclosure quality [1] Group 2: Tianfeng Securities - Tianfeng Securities also received a notice from the CSRC for suspected information disclosure violations and illegal financing [4] - The company stated that its operations are normal and it will cooperate with the investigation while adhering to disclosure obligations [4] Group 3: Yuanda Intelligent - Yuanda Intelligent received a preliminary penalty notice from the Liaoning Securities Regulatory Bureau for falsely recognizing elevator sales revenue using forged acceptance certificates, affecting multiple annual reports [8] - The bureau plans to issue a warning and impose a fine of 6 million yuan on the company [8] Group 4: Puli Pharmaceutical - Puli Pharmaceutical, which has been delisted, received a preliminary penalty notice for failing to disclose its 2024 annual report on time [11] - The company is facing a warning and a fine of 500,000 yuan from the Hainan Securities Regulatory Bureau [11] Group 5: ST Shenhua - ST Shenhua received an administrative penalty decision from the Liaoning Securities Regulatory Bureau for manipulating financial data from 2018 to 2021, resulting in false records in annual reports [17][18] - The company was fined 7 million yuan and received a warning, with penalties also proposed for other involved parties [17][18]

Core Insights - The animal nutrition industry is crucial for global food safety and health, facing challenges due to rising protein demand and limited resources, necessitating technological innovation and sustainable development [1][2] - Andy Su, a leader in the methionine sector, aims to transition towards sustainability, substitution, and efficiency, with technological innovation as a key driver for industry upgrades [1][2] Company Strategy - Andy Su's core product, "Rhodimet®," holds a nearly 30% global market share in 2024, supporting revenue and profit growth [2] - The company plans to enhance production capacity, with a 40,000-ton increase at its European base by year-end and a similar expansion at its Nanjing facility by the end of 2026 [2] - A new 150,000-ton solid methionine project in Quanzhou, Fujian, is set to begin trial operations next year [2] - Andy Su is expanding its high-value specialty products, targeting a 20% revenue contribution from new products over the next five years [2][3] Research and Development - The company invests at least 3% of its revenue annually in R&D, focusing on process optimization and new product development [3] - An innovation fund of €1 million is established every three years to address common industry challenges [3] - The company is exploring alternative protein sources and sustainable development trends, integrating ESG (Environmental, Social, and Governance) into its core strategy [3][4] Global Operations - Andy Su has adopted a strategy of "bringing in" and "going out," enhancing its production capacity in Nanjing and exporting products to Southeast Asia, South America, and India [5] - The company operates two major production bases in Europe and China, creating a complementary global supply system [5] - Future plans include optimizing the global supply network and enhancing service quality in key markets [5][6] Financial Performance and Investor Relations - Over the past decade, Andy Su has distributed a total of 4.6 billion yuan in dividends to investors [5] - The company emphasizes investor relations management and aims to communicate its strategic plans and growth prospects effectively [5][6]

Core Insights - The animal nutrition industry is crucial for global food safety and health, facing challenges due to rising protein demand and limited resources, necessitating technological innovation and sustainable development [1] - Andy Su, a leader in the animal nutrition additives sector, emphasizes the industry's future direction towards sustainability, substitution, and efficiency, with technological innovation as the core driver for resolving supply-demand conflicts [1] Group 1: Business Strategy - Andy Su's core product, "Rhodimet®," holds a nearly 30% global market share in the methionine sector, providing strong support for revenue and profit growth [2] - The company plans to enhance its production capacity, with an additional 40,000 tons expected at its European base by the end of the year and a similar increase at its Nanjing plant by the end of 2026 [2] - Andy Su is expanding its high-value specialty products business, which includes products that enhance digestion, ruminant products, and health and nutrition products, targeting a 20% revenue contribution from new products over the next five years [3] Group 2: R&D and ESG Commitment - The company invests at least 3% of its revenue annually in R&D, focusing on internal process optimization and new product development, while also establishing a €1 million innovation fund every three years to address industry challenges [3] - Andy Su integrates ESG (Environmental, Social, and Governance) principles into its core strategy, elevating ESG management to the decision-making level by upgrading its strategic committee [3] - Innovative products like FeedKind® protein, produced through natural gas fermentation, and wastewater recycling projects demonstrate the company's commitment to sustainability and resource efficiency [4] Group 3: Global Operations - As it approaches its 10th anniversary, Andy Su has successfully integrated European technology and production capabilities, increasing its Nanjing plant's capacity from 170,000 tons to 350,000 tons, making it the largest and most cost-competitive liquid methionine production facility globally [5] - The company combines global integration with localized operations, optimizing its supply network to match regional market characteristics and enhance service quality [5] - Andy Su has distributed a total of 4.6 billion yuan in dividends to investors over the past decade, emphasizing its commitment to investor relations and transparent communication [5]